


Acute myeloid leukemia with *NUP98::HOXA9* mimicking acute promyelocytic leukemia

Elisa Lin and Weina Chen, University of Texas Southwestern Medical Center



A 56-year-old woman was admitted for anemia (hemoglobin, 7.8 g/dL) and thrombocytopenia (platelets, 25 000/ μ L), which was concerning for acute myeloid leukemia (AML). The peripheral blood (PB) and bone marrow (BM) aspirate smears showed numerous hypergranular promyelocytes with Auer rods (panels A and B, black arrows; Wright-Giemsa stain on BM aspirate; 100 \times objective). Flow cytometric study on BM aspirate (panel C) demonstrated abundant promyelocytes (62%) with high side scatter (corroborating hypergranularity) and CD34^{partial+}/human leukocyte antigen (HLA)-DR^{predominantly-}/CD15^{partial+}/CD117⁺. There was a mild increase in D-dimer (2.31 μ g/L; reference value, \leq 0.59 μ g/L). These findings were suspicious for acute promyelocytic leukemia (APL). The patient was initially treated with all-*trans* retinoic acid, but treatment was discontinued once fluorescence in situ hybridization studies

indicated an *NUP98* rearrangement but no evidence of *PML::RARA* or *RARA* rearrangement. Cytogenetics revealed an isolated 46,XX,t(7;11)(p15;p15), resulting in the *NUP98::HOXA9* fusion that was confirmed by next-generation sequencing (NGS) (additional *TET2* [p.Leu1229Arg and p.Gln635*] detected). The patient was started on standard induction chemotherapy with the 7 + 3 regimen.

To our knowledge, this is the first case of *NUP98::HOXA9* rearranged AML that morphologically and immunophenotypically resembles APL; notably, *NUP98::RARA* fusion has been recently reported in APL. This case highlights the importance of combining different techniques (PB/BM examination, flow cytometry, cytogenetics, and NGS) to identify driver lesions and select appropriate therapies.